Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Viruses shown to cause bowel dysfunction and abdominal pain

Viruses known to target the central nervous system may also affect neurons of the digestive tract, causing bowel dysfunction and abdominal pain.

4 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Tips to know your ovarian cancer risk and symptoms

Ovarian cancer is the fifth leading cause of death in American women, according to the American Cancer Society, and accounts for more deaths than any other cancer of the female reproductive system. And according to the National Cancer Institute, approximately 22,240 women will be diagnosed with the disease in 2018; 14,070 will die from it.

28 Aug 2018

Low dose Aspirin daily – benefits and risks measured in two studies

Low dose Aspirin has been advocated to reduce the risk of a second heart attack or a stroke or other heart problems in persons who have had one episode. A major new study published in the Lancet, has found that taking Aspirin to prevent the first heart attack fails to work. In fact the risks of taking low dose Aspirin to prevent the first heart attack outweigh the benefits.

27 Aug 2018

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late breaking results from the ARRIVE study presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in the Lancet.

27 Aug 2018

FDA approves first vaginal ring contraceptive that can be used for one year

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

10 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

Study: 11% of IBS-D patients suffer from suicidal thinking when their condition is bad

Eleven percent of irritable bowel syndrome with diarrhoea (IBS-D) patients reveal that they suffer from suicidal thinking when their condition is bad, a new study has found.

10 Aug 2018

FDA approves potassium chloride oral solution as first generic drug to receive CGT designation

The U.S. Food and Drug Administration today approved several strengths of potassium chloride oral solution as the first generic drugs to receive a Competitive Generic Therapy designation.

9 Aug 2018

Probiotic use could result in disorienting brain fogginess and rapid belly bloating

Probiotic use can result in a significant accumulation of bacteria in the small intestine that can result in disorienting brain fogginess as well as rapid, significant belly bloating, investigators report.

6 Aug 2018

Clinical trial to use stem cell transplants for treating Crohn's disease

A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn's disease - a painful and chronic intestinal disease which affects at least 115,000 people in the UK.

6 Aug 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Abdominal Pain News and Research

Further Reading

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Viruses shown to cause bowel dysfunction and abdominal pain

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Tips to know your ovarian cancer risk and symptoms

Low dose Aspirin daily – benefits and risks measured in two studies

ARRIVE study assesses impact of daily aspirin on heart attacks, strokes

FDA approves first vaginal ring contraceptive that can be used for one year

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

Study: 11% of IBS-D patients suffer from suicidal thinking when their condition is bad

FDA approves potassium chloride oral solution as first generic drug to receive CGT designation

Probiotic use could result in disorienting brain fogginess and rapid belly bloating

Clinical trial to use stem cell transplants for treating Crohn's disease

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News